VRTX - Vertex Pharmaceuticals Incorporated
| Previous Close | 240.09 |
| Open | 241.24 |
| Bid | 225.00 x 900 |
| Ask | 244.00 x 900 |
| Day's Range | 238.60 - 244.45 |
| 52 Week Range | 163.68 - 249.00 |
| Volume | 1,354,016 |
| Avg. Volume | 1,365,857 |
| Market Cap | 63.215B |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | 54.06 |
| EPS (TTM) | 4.51 |
| Earnings Date | Apr 27, 2020 - May 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 266.60 |
- Zacks
What's in Store for Vertex in 2020 After a Remarkable 2019?
In 2020, Vertex's (VRTX) sales are expected to be primarily driven by Trikafta and higher international revenues.
- Barrons.com
Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy.
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
- Zacks
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
- Thomson Reuters StreetEvents
Edited Transcript of VRTX earnings conference call or presentation 30-Jan-20 9:30pm GMT
Q4 2019 Vertex Pharmaceuticals Inc Earnings Call
- Investor's Business Daily
How This IBD Stock Of The Day Clawed Its Way Above Two Buy Points
Vertex Pharmaceuticals is the IBD Stock Of The Day as shares of the biotech company offer new buying opportunities following the launch of Trikafta in cystic fibrosis treatment.
- Zacks
3 Reasons Growth Investors Will Love Vertex (VRTX)
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
- Zacks
Why Vertex (VRTX) Might be Well Poised for a Surge
Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- Zacks
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
Is (VRTX) Outperforming Other Medical Stocks This Year?
- Zacks
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
- Investor's Business Daily
Biotech Stocks Ran Up In 2019 — Who's Leading The Pack For 2020?
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
- Zacks
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
NASDAQ Reaches New Closing High as Rebound Continues
NASDAQ Reaches New Closing High as Rebound Continues
- Zacks
Buy this Cloud-Based Business Services Stock After Earnings on Strong Growth?
ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...
- GuruFocus.com
Eaton Vance Exits Celgene, Trims Amgen Position
Health care-focused fund's largest sales of the 4th quarter Continue reading...
- Simply Wall St.
Earnings Beat: Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) just released its latest full-year results and things are looking...
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- TheStreet.com
Don't Underestimate Vertex Pharmaceuticals
During the Lightning Round segment of Mad Money Thursday night one caller asked Jim Cramer about Vertex Pharmaceuticals Inc. : "Wall Street underestimates this stock," said Cramer. In the daily bar chart of VRTX, below, we can see that the stock price turned up strongly from early October when the broad market started its fourth-quarter rally. The daily On-Balance-Volume (OBV) line started its rise in early October and tells us that buyers of VRTX have been more aggressive.
- Investor's Business Daily
Dow Jones Falls On Coronavirus Fears; Amazon Leads 3 Stocks Flashing Buy Signals
Dow Jones futures fell on coronavirus fears. Amazon stock surged on earnings, leading 3 stocks flashing possible buys. IBM CEO Ginni Rometty is leaving.
- Benzinga
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- Barrons.com
Vertex’s Cystic Fibrosis Therapy Looks Like a Hit. Early Sales Shocked the Street.
The biotech firm said it has sold $420 million worth of its new cystic fibrosis therapy—five times the amount analysts had anticipated.
- American City Business Journals
Families of rare-disease patients take on drug development, but face uphill battle
Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.
- Zacks
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily
Top Biotech Vertex Pops After Crushing Fourth-Quarter Expectations
Late Thursday, Vertex Pharmaceuticals reported adjusted income of $1.70 per share on $1.41 billion in revenue for its fourth quarter ended Dec. 31. As a result, VRTX stock popped.
- MarketWatch
Vertex Pharma stock rises on earnings, outlook beat
Vertex Pharmaceuticals Inc. shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates. Vertex shares rose 2.9% after hours, following a 0.9% decline in the regular session to close at $230.31. The company reported fourth-quarter net income of $583.2 million, or $2.23 a share, compared with $1.55 billion, or $5.97 a share, in the year-ago period. Adjusted earnings were $1.70 a share versus $1.30 a share in the year-ago period. Revenue rose to $1.41 billion from $870.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $1.21 a share on revenue of $1.01 billion. Vertex expects "total product" revenue of $5.1 billion to $5.3 billion in 2020, while analysts had forecast on revenue of $4.88 billion.
